|
Medication Therapy Management
|
N02.421.668.438 |
|
|
Pulp Capping and Pulpectomy Agents
|
D27.720.102.339.500 |
|
|
Dental Materials
|
D27.720.102.339 |
|
|
Behcet Syndrome
|
C17.800.827.368.250 |
|
|
Hereditary Autoinflammatory Diseases
|
C17.800.827.368 |
|
|
Liver Regeneration
|
G16.762.468 |
|
|
Regeneration
|
G16.762 |
|
|
Cell- and Tissue-Based Therapy
|
D064987 |
[Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
] |
|
Pseudophakia
|
C23.888.681 |
|
|
Resveratrol
|
D02.455.426.559.389.657.715.500 |
|
|
Polyphenols
|
D02.455.426.559.389.657.715 |
|
|
Thiamylal
|
D03.383.742.698.253.800.750 |
|
|
Thiobarbiturates
|
D03.383.742.698.253.800 |
|
|
Brugada Syndrome
|
C14.280.123.250 |
|
|
Cardiac Conduction System Disease
|
C14.280.123 |
|
|
Bronchopulmonary Sequestration
|
C08.695.214 |
|
|
Retinoic Acid 4-Hydroxylase
|
D08.811.682.690.708.170.485.500 |
|
|
Cytochrome P450 Family 26
|
D08.811.682.690.708.170.485 |
|
|
Streptogramin B
|
D025381 |
[A specific streptogramin group B antibiotic produced by Streptomyces graminofaciens and other bacteria.
] |
|
Streptogramin Group B
|
D025382 |
[A structural subclass of streptogramins. They are cyclic hexadepsipeptides with approximate molecular weight of 800 that contain a characteristic 3-hydroxy picolinoyl exocyclic component.
] |
